Use of a Minimal PBPK Model to Investigate the Effect of Shed Antigen on Simulated Trastuzumab in Humans
Evaluating the Impact of Extended Release Formulations on Absorption and Gut-wall Metabolism Using a Physiologically-based Pharmacokinetic Simulation Approach
Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model
Comparison of the Catalytic Activity per Unit Enzyme of Recombinantly Expressed and Human Liver Microsomal Cytochrome P450 2C9: Determination of Inter System Extrapolation Factors
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. It is primarily metabolized by CY2B6. A standard dose of efavirenz has been associated with serious adverse reactions in poor metabolizers (PMs) of CYP2B6, necessitating a reduction […]
Using PBPK modeling, researchers predicted multiple-dose exposure levels and optimized the design of a DDI study for a compound exhibiting auto-inhibition.
New biosimulation solution addresses drug candidates’ cardiotoxicity risk PRINCETON, NJ – Apr. 2, 2015 – Certara®, the global biosimulation technology-enabled consultancy, today announced the launch of version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is currently being used by several leading pharma companies, two […]